MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on May 4, 2006; DOI: 10.1124/mol.105.020644


0026-895X/06/7002-667-675$20.00
Mol Pharmacol 70:667-675, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.020644v1
70/2/667    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peterson, B. Z.
Right arrow Articles by Catterall, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peterson, B. Z.
Right arrow Articles by Catterall, W. A.

Allosteric Interactions Required for High-Affinity Binding of Dihydropyridine Antagonists to CaV1.1 Channels Are Modulated by Calcium in the Pore

Blaise Z. Peterson, and William A. Catterall

Department of Cellular and Molecular Physiology, The Penn State Milton S. Hershey College of Medicine, Hershey, Pennsylvania (B.Z.P.); and Department of Pharmacology, University of Washington, Seattle, Washington (W.A.C.)

Dihydropyridines (DHPs) are an important class of drugs, used extensively in the treatment of angina pectoris, hypertension, and arrhythmia. The molecular mechanism by which DHPs modulate Ca2+ channel function is not known in detail. We have found that DHP binding is allosterically coupled to Ca2+ binding to the selectivity filter of the skeletal muscle Ca2+ channel CaV1.1, which initiates excitation-contraction coupling and conducts L-type Ca2+ currents. Increasing Ca2+ concentrations from approximately 10 nM to 1 mM causes the DHP receptor site to shift from a low-affinity state to a high-affinity state with an EC50 for Ca2+ of 300 nM. Substituting each of the four negatively charged glutamate residues that form the ion selectivity filter with neutral glutamine or positively charged lysine residues results in mutant channels whose DHP binding affinities are decreased up to 10-fold and are up to 150-fold less sensitive to Ca2+ than wild-type channels. Analysis of mutations of amino acid residues adjacent to the selectivity filter led to identification of Phe-1013 and Tyr-1021, whose mutation causes substantial changes in DHP binding. Thermo-dynamic mutant cycle analysis of these mutants demonstrates that Phe-1013 and Tyr-1021 are energetically coupled when a single Ca2+ ion is bound to the channel pore. We propose that DHP binding stabilizes a nonconducting state containing a single Ca2+ ion in the pore through which Phe-1013 and Tyr-1021 are energetically coupled. The selectivity filter in this energetically coupled high-affinity state is blocked by bound Ca2+, which is responsible for the high-affinity inhibition of Ca2+ channels by DHP antagonists.


Received November 11, 2005; accepted May 4, 2006

Address correspondence to: Dr. Blaise Z. Peterson, Cellular and Molecular Physiology, H166, Penn State Milton S. Hershey Medical Center, College of Medicine, 500 University Dr., Room C6603, P.O. Box 850, Hershey, PA 17033-0850. E-mail: bpeterson{at}psu.edu




This article has been cited by other articles:


Home page
Biophys. JHome page
Y. Shafrir, S. R. Durell, and H. R. Guy
Models of the Structure and Gating Mechanisms of the Pore Domain of the NaChBac Ion Channel
Biophys. J., October 15, 2008; 95(8): 3650 - 3662.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics